Women’s health month marks a turning point in women’s care
March is Women’s Month, a time not only for recognition but also for awareness. In health care, awareness can directly influence outcomes. New research, regulatory changes, and medical technologies are changing how diseases affecting women are detected, treated, and prevented. Knowing about these developments allows women to make informed decisions and seek timely care.
This observance is also an opportunity to reassess personal health decisions using current information. Whether it involves discussing AI-assisted mammography, reconsidering hormone therapy, seeking evaluation for endometriosis, or assessing heart risk, informed patients are better positioned to pursue appropriate care.
Across oncology, reproductive health, cardiology, infectious disease, and digital medicine, 2025 has brought measurable progress.
AI screening in breast cancer
Breast cancer screening is entering a new phase with the integration of artificial intelligence (AI). In June 2025, the US Food and Drug Administration (FDA) cleared Clairity Breast, the first AI tool designed to predict a woman’s personalized five-year risk of breast cancer using a standard mammogram. Large clinical trials have also shown that AI-assisted workflows detect breast cancer at a rate 21.6% higher than traditional screening methods. Researchers estimate that AI integration could reduce interval breast cancers — those found between regular screenings — by up to 30%.
AI applications are also extending beyond mammography. In 2024, an AI-based software from 16 Bit Inc. was approved to use standard X-rays to prescreen for low bone mineral density, a major risk factor for osteoporosis in women.
For women, the implication is clear: screening is becoming more precise and potentially more predictive. Staying informed about updated screening tools may influence discussions with health providers about risk and testing frequency.
AI expands to preventive and early detection modalities
AI is expanding beyond imaging. Portable AI-enabled ultrasound devices are being tested in Kenya and South Africa to identify high-risk pregnancies and estimate gestational age.
Wearables such as Oura Ring are collecting data on perimenopause, sleep, and cardiovascular markers from large user populations. Researchers are also applying AI to analyze blood biomarkers and medical records to detect early signs of Alzheimer’s disease in women, who represent two-thirds of patients globally.
Progress in endometriosis treatment
Endometriosis affects an estimated 190 million women and girls worldwide. Historically, diagnosis has taken an average of eight years, and treatment options have been limited.
In 2025, several advances emerged, including Linzagolix (Yselty) , which was approved in the UK as a new daily pill for managing symptoms, marking the first new NHS-backed treatment in years; Dichloroacetate (DCA), originally developed for cancer, is showing promise as a non-hormonal therapy in early research; Merigolix, a GnRH antagonist in clinical trials, significantly reduced menstrual pain within 12 weeks; as well, a non-invasive diagnostic tool, maraciclatide, received FDA Fast Track designation.
Genetic studies have identified links between endometriosis and 11 other conditions, including migraine, asthma, chronic pain, and osteoarthritis.
For patients who have long faced delayed diagnosis and limited options, these developments suggest that both treatment and understanding of the condition are evolving.
Menopause and hormone therapy
Menopause management has long been approached with caution, particularly regarding hormone replacement therapy (HRT). In November 2025, the FDA announced plans to remove long-standing “black box” warnings from menopausal HRT products.
New evidence indicates that women who begin HRT within ten years of menopause onset, generally before age 60, experience a reduction in all-cause mortality. Long-term follow-up studies also show that estrogen-alone therapy was associated with a 22% reduction in breast cancer.
Despite this, only about one in four women seek treatment for menopause symptoms. Virtual clinics and wearable devices are beginning to close this gap by offering easier access to evaluation and monitoring.
Understanding these regulatory changes allows women to revisit conversations about menopause treatment with updated evidence in mind.
Cervical cancer prevention
Cervical cancer remains the fourth most common cancer among women globally, causing approximately 350,000 deaths annually. Ninety percent of these deaths occur in low- and middle-income countries.
Research now confirms that a single dose of the HPV vaccine is as effective as a two-dose schedule, improving accessibility worldwide.
In addition, a Phase II trial of the therapeutic HPV vaccine Vvax001 demonstrated regression of precancerous lesions in half of participants. Unlike preventive vaccines, therapeutic vaccines treat women who already have lesions, potentially reducing the need for invasive procedures.
For global health equity, these findings may significantly influence screening and vaccination strategies.
Maternal health innovations in pre- and post-birth
Maternal health remains a priority area, particularly in resource-limited settings.
Researchers at Monash University in Australia developed an inhalable, dry-powder form of oxytocin to prevent postpartum hemorrhage, the leading cause of maternal death worldwide. Unlike injectable forms, it does not require refrigeration.
FHI 360 launched human trials of Casea S, the first biodegradable contraceptive implant in over 20 years.
MZe786, an investigational oral drug for preeclampsia, has shown improved outcomes in early studies.
Non-invasive prenatal testing (NIPT) continues to expand screening capabilities for chromosomal abnormalities.
These tools target critical moments in pregnancy and childbirth, where timely intervention can save lives.
Cardiovascular disease as a persistent medical issue
Cardiovascular disease remains the leading cause of death and disability among women in the US. Historically, women have been underdiagnosed because medical training focused on male symptom patterns.
Recent projections estimate that six in ten US women could have some form of cardiovascular disease by 2050.
New developments include: Baxdrostat, a medication for resistant hypertension; GLP-1 receptor agonists such as tirzepatide and oral semaglutide, which show cardiovascular benefits beyond diabetes management; and Stem cell research demonstrating the potential to restore heart muscle.
Updated guidelines from the American Heart Association (AHA) acknowledging menopause as a cardiovascular risk factor.
For women, understanding sex-specific risks, including conditions like preeclampsia and gestational diabetes, can influence long-term heart health planning.
Category: Top Story
